| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_98ac7d4cede02bd3e09838630e8562c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d93a3fdd031e483c033ce2641aca024b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66bce9cb071741961f540cff6c647803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_428dff815117552ee70287dd153805cb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b9ecd28810db421823f637142302487 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-02 |
| filingDate |
2010-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fae049d32a7119db18b58d47698e962
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f67cce1b721ab665af18e20f84c9d05e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44fd72195b31abe157a6d40760a693bf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c089661f883394328c167bfcd3aff4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb2fc7fb273ca1fc153821935dfb08f8 |
| publicationDate |
2011-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011189652-A1 |
| titleOfInvention |
Viral variants with altered susceptability to nucloeside analogs and uses thereof |
| abstract |
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8367317-B2 |
| priorityDate |
2002-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |